---
title: "4D-150 in Neovascular age-related macular degeneration: Clinical evidence"
description: "Formulary evidence on 4D-150 in Neovascular age-related macular degeneration: Clinical evidence. Covers 4FRONT-1, 4FRONT-2, PRISM phase 2a dose expansion, PRISM phase 2b population extension, and PRISM phase 1 dose exploration. 180 evidence topics quoted from 46 sources."
canonical: "https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/clinical-evidence"
published: "2026-09-17T18:33:01-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# 4D-150 in Neovascular age-related macular degeneration: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 4FRONT-1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Registered study title and purpose

> “A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration”

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.1-2"></a>

###### Primary objective as described by the sponsor

> “Noninferiority in mean change in BCVA from baseline to Week 52 for a single injection of 4D-150 vs. aflibercept 2mg (Q8W) after 3 loading doses”

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

> “The primary endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity (BCVA) at 52 weeks. The key secondary endpoint is treatment burden reduction comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm over 52 weeks.”

Source: [4D Molecular Therapeutics 4FRONT-1 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/02/09/3234480/0/en/4DMT-Completes-Enrollment-for-4FRONT-1-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Summary: sites and timeline

The ClinicalTrials.gov record for 4FRONT-1 (protocol 4D-150-C003) lists 95 sites: 91 in the United States and 4 in Canada. The study started on 2025-03-03; enrollment was completed in February 2026 and randomization in March 2026. Primary completion is estimated for June 2027 and study completion for June 2028, and the sponsor expects 52-week topline data in the second quarter of 2027.

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988); [4D Molecular Therapeutics second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm)

<a id="topic-3.1.1.2-2"></a>

###### Study dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2025-03-03” |
| Primary completion (estimated) | “2027-06” |
| Study completion (estimated) | “2028-06” |

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.2-3"></a>

###### Region and first enrollment

> “4FRONT-1 is evaluating treatment naïve wet AMD patients at sites in North America.”
> “EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (wet AMD).”

Source: [4D Molecular Therapeutics 4FRONT-1 first patients announcement (2025)](https://www.globenewswire.com/news-release/2025/03/10/3039669/0/en/4DMT-Announces-First-Patients-Enrolled-in-4FRONT-1-Phase-3-Clinical-Trial-Evaluating-4D-150-in-Wet-AMD.html)

<a id="topic-3.1.1.2-4"></a>

###### Enrollment completion and topline timing

> “Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in Q2 2027”

Source: [4D Molecular Therapeutics second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm)

> “In March 2025, we initiated 4FRONT-1, our first Phase 3 trial of 4D-150 in wet AMD. Subsequently in February 2026, we announced enrollment completion within an approximately 11-month period, ahead of initial projections, with the clinical trial overenrolled and 523 patients randomized, reflecting strong interest from investigators and patients. We anticipate topline data for 4FRONT-1 in the second quarter of 2027.”

Source: [4D Molecular Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349173/fdmt-20260630.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Phase 3 randomized, double-masked, aflibercept-controlled design

> “4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled study of intravitreal 4D-150 in wet AMD.”
> “Patients in both arms will be eligible for supplemental aflibercept injections.”

Source: [4D Molecular Therapeutics 4FRONT-1 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/02/09/3234480/0/en/4DMT-Completes-Enrollment-for-4FRONT-1-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

<a id="topic-3.1.1.3-2"></a>

###### Registered design elements

| Design element | Registry record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.3-3"></a>

###### Aflibercept run-in and response-based randomization

> “Enrolling selected population to reduce variability:”
> “Excluded outlier baseline anatomy (high CST) that drives variability”
> “Randomizing strong aflibercept responders only”
> “Durezol® taper (both arms) starting Day -3”

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.1.3-4"></a>

###### Design as first disclosed in 2024, including masking and FDA alignment

> “Program expected to include two double-masked, randomized, controlled noninferiority trials: Primary endpoint: noninferiority in BCVA”
> “Sham controlled to support masking”
> “All patients randomized to receive 3 total loading doses per aflibercept label”
> “Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; no supplemental injections allowed in control arm”
> “Study design has been aligned with feedback from U.S. Food and Drug Administration (FDA) under RMAT designation”
> “Alignment ongoing with European Medicines Agency (EMA) under PRIME designation”

Source: [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and)

<a id="topic-3.1.1.3-5"></a>

###### Global program structure

> “The 4FRONT global Phase 3 registration program consists of two multicenter, randomized, double masked, aflibercept Q8W comparator-controlled trials, with the primary endpoint of BCVA noninferiority of 4D-150 3E10 vg/eye to aflibercept 2mg Q8W at 52 weeks.”

Source: [4D Molecular Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Age | “≥50 years of age at time of consent” |
| Treatment history | “Treatment naïve MNV secondary to nAMD in the study eye” |
| Disease activity | “Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT), in the study eye, at the Screening Visit confirmed by the Reading Center” |
| Aflibercept response | “Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center” |
| Visual acuity | “BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit” |
| Retinal thickness | “CST less than or equal to 500 microns in the study eye at screening visit, confirmed by the central reading center” |

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.4-2"></a>

###### Key exclusion criteria

> “History of retinal detachment in the study eye”
> “History of or presence of active inflammation in either eye”
> “Glaucoma or intraocular hypertension requiring more than 2 topical medications for control”
> “Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit”
> “History of autoimmune condition that may predispose to the development of uveitis”

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.4-3"></a>

###### Aflibercept response criterion for randomization

> “≥15% reduction in CST or complete resolution of intraretinal and/or subretinal fluid”
> “Determined by SD-OCT and confirmed by an independent Reading Center.”

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.1.4-4"></a>

###### Population disclosed in 2024 design

> “Eligibility criteria: 1) Patients must be both recently diagnosed and treatment naïve wet AMD patients, and 2) Randomization requires on study demonstration of aflibercept responsiveness”

Source: [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Summary: dosing schedule

According to the sponsor's trial schedule, participants in both arms receive aflibercept 2 mg at Weeks -5 and -1 and are randomized on Day 1, when the 4D-150 arm receives a single intravitreal injection of 4D-150 3E10 vg/eye and the aflibercept arm receives a sham injection. Both arms receive aflibercept at Week 4 (the third loading dose). From Week 12 through Week 52 the aflibercept arm receives aflibercept every 8 weeks and the 4D-150 arm receives sham injections at the same visits. Both arms receive a Durezol (difluprednate) taper starting on Day -3, and both arms are eligible for supplemental aflibercept when protocol-defined disease activity criteria are met.

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d); [4D Molecular Therapeutics 4FRONT-1 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/02/09/3234480/0/en/4DMT-Completes-Enrollment-for-4FRONT-1-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

<a id="topic-3.1.1.5-2"></a>

###### Treatment arms

| Arm | Quoted registry description |
| --- | --- |
| 4D-150 IVT (3E10 vg/eye), experimental | “If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1” |
| Aflibercept (AFLB) 2 mg IVT, active comparator | “Eylea (aflibercept) will be administered at applicable visits” |

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.5-3"></a>

###### Supplemental aflibercept criteria

| Criterion | Quoted presentation text |
| --- | --- |
| Arms eligible | “Supplemental Aflibercept Criteria (Both arms)” |
| BCVA reference value | “BCVA: Average of Week 4 & 8” |
| CST reference value | “CST: Week 8” |
| Vision and anatomy | “Vision & Anatomy: ≥5 letter loss in BCVA AND ≥50 µm increase in CST” |
| Vision | “Vision: ≥10 letter loss in BCVA” |
| Anatomy | “Anatomy: ≥100 µm increase in CST” |
| Hemorrhage | “New vision-threatening hemorrhage” |
| Investigator discretion | “PI discretion not allowed.” |

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.1.5-4"></a>

###### Dose selection

> “The Phase 2b trial enrolled 45 patients at two dose levels of a single intravitreal dose of 4D-150 (3E10 and 1E10 vg/eye); 3E10 vg/eye was chosen as the dose for the 4FRONT Phase 3 clinical trials”

Source: [4D Molecular Therapeutics Form 8-K PRISM 2-year data (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Best Corrected Visual Acuity as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Registry record | Time frame |
| --- | --- | --- |
| Primary | “Mean change from baseline in BCVA ETDRS letter score at Week 52” | “52 Weeks” |
| Secondary | “Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104” | “104 Weeks” |
| Secondary | “Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104” | “104 Weeks” |
| Secondary | “Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm” | “104 Weeks” |
| Secondary | “Mean change from baseline in CST over time through Weeks 52 and 104” | “104 Weeks” |
| Secondary | “Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104” | “104 Weeks” |

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.6.1-2"></a>

###### Noninferiority margins: FDA and ex-US regulators

> “As previously disclosed, the 4FRONT Trials were initiated to provide >90% power for a primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks with a margin of 4.5 letters (in accordance with U.S. Food and Drug Administration guidance).”
> “The increase in target enrollment in the 4FRONT Trials is designed to provide approximately 90% power with a noninferiority margin of approximately 4 letters outside of FDA jurisdiction such as Japan Pharmaceuticals and Medical Devices Agency and European Medicines Agency.”

Source: [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm)

<a id="topic-3.1.1.6.1-3"></a>

###### Supplemental criteria designed to protect the BCVA endpoint

> “Optimized Supplemental Criteria”
> “Protects BCVA”
> “Clinically relevant treatment burden reduction result”

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.1.6.1-4"></a>

###### FDA guidance on selecting a noninferiority margin

> “It is therefore usual in NI studies to choose a smaller margin (M2) that reflects the largest loss of effect that would be clinically acceptable.”
> “Note that a larger value for M2 may be justified clinically, if the test drug were shown to have some important advantage (e.g., on safety or on a secondary endpoint).”

Source: [FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016)](https://www.fda.gov/media/78504/download)

<a id="topic-3.1.1.6.1-5"></a>

###### Derivation of a 4-letter margin from historical anti-VEGF trials

> “The non-inferiority margin is based on data from the MARINA ranibizumab pivotal nAMD study and is also supported by both data from the ANCHOR ranibizumab pivotal nAMD study and the VIEW1 and VIEW2 aflibercept pivotal nAMD studies.”
> “At 1 year, in MARINA, patients receiving 0.5 mg of ranibizumab every month gained 6.3 letters from baseline compared with a loss of 11.0 letters for patients in the control arm. The 4-letter non-inferiority margin preserves approximately 70% of the least estimated benefit of ranibizumab over sham control in the MARINA study.”
> “From a clinical perspective, the non-inferiority margin should be fewer than 5 letters, given that a loss of 5 letters (one ETDRS line) between treatments would be considered clinically relevant.”

Source: [Hoffmann-La Roche TENAYA protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/87/NCT03823287/Prot_000.pdf)

<a id="topic-3.1.1.6.1-6"></a>

###### A 4.5-letter margin in a prior nAMD phase 3 trial versus aflibercept

> “The maximum clinically acceptable true difference between KSI-301 and aflibercept among wAMD patients to be considered non-inferior is 4.5 ETDRS letters, i.e. the non-inferiority margin (NI) is 4.5 letters.”

Source: [Kodiak Sciences DAYLIGHT statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04964089/SAP_001.pdf)

<a id="topic-3.1.1.6.1-7"></a>

###### Margins used in recent nAMD registration trials

> “The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population.”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

> “The least squares mean differences between aflibercept 8q12 versus 2q8 and 8q16 versus 2q8, respectively, were -0·97 (95% CI -2·87 to 0·92) and -1·14 (-2·97 to 0·69) letters (non-inferiority margin at 4 letters).”

Source: [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="topic-3.1.1.6.1-8"></a>

###### Shift to noninferiority designs in nAMD after MARINA and ANCHOR

> “Because no FDA-approved drug to date has demonstrated a statistically significant improvement over monthly ranibizumab in preventing a 15-letter loss of visual acuity, clinical trials pivoted toward demonstrating noninferiority.”
> “Because a placebo arm is not present in noninferiority studies, the effect of the active control relative to placebo is inferred on past randomized controlled trials, in this case MARINA and ANCHOR.”
> “In ASCENT, a phase 3 clinical trial for ABBV-RGX-314 gene therapy (Regenxbio), investigators determined that a primary outcome of noninferiority in BCVA change at 1 year from baseline compared to biweekly aflibercept was most suitable, though rescue therapy was permissible.”

Source: [Silva (2024)](https://www.retinalphysician.com/issues/2024/october/the-evolution-of-clinical-trial-endpoints-for-wet-amd/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Estimated | “480” |

Source: [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="topic-3.1.1.7.1-2"></a>

###### Sample size and power

> “Target enrollment per study is 480 patients randomized 1:1 to 4D-150 or the aflibercept comparator arm, providing approximately 90% power with a noninferiority margin of 4 letters as aligned with the Japan Pharmaceuticals and Medical Devices Agency and EMA and over 90% power with a noninferiority margin of 4.5 letters per FDA guidance.”

Source: [4D Molecular Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm)

<a id="topic-3.1.1.7.1-3"></a>

###### Protocol amendment increasing target enrollment

> “On December 10, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) announced its intention to implement protocol amendments (the “Amendments”) to the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials of 4D-150 in wet AMD (the “4FRONT Trials”) to increase target enrollment from 400 to 480 patients per trial.”
> “4FRONT-1 has 300 patients randomized or approved to randomize as of December 10, 2025.”

Source: [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm)

<a id="topic-3.1.1.7.1-4"></a>

###### Randomized participants

> “4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients”

Source: [4D Molecular Therapeutics 4FRONT-1 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/02/09/3234480/0/en/4DMT-Completes-Enrollment-for-4FRONT-1-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

> “Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in Q2 2027”

Source: [4D Molecular Therapeutics second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm)

<a id="topic-3.1.1.7.1-5"></a>

###### Analyzed population

No evidence found.

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

No results have been reported as of September 2026; 523 participants were randomized and 52-week topline data are expected in the second quarter of 2027. The trial tests noninferiority rather than superiority for BCVA, with a margin of 4.5 letters for the FDA and approximately 4 letters for EMA and PMDA; a 4.5-letter margin is wider than the 4-letter margin prespecified in the faricimab (TENAYA and LUCERNE) and aflibercept 8 mg (PULSAR) registration trials. Participants in both arms can receive supplemental aflibercept, so the 52-week BCVA comparison measures 4D-150 plus as-needed aflibercept against fixed aflibercept every 8 weeks, and the key secondary endpoint (number of aflibercept injections) depends on the supplemental criteria, which exclude investigator discretion. The sponsor's 2024 design stated that no supplemental injections would be allowed in the control arm, whereas 2025 and 2026 disclosures state that both arms are eligible. Enrollment is restricted to treatment-naive participants in the United States and Canada with BCVA of 25 to 78 letters, CST of 500 µm or less, and a documented anatomic response to aflibercept during a run-in (15% or greater CST reduction or fluid resolution), which the sponsor describes as selecting strong aflibercept responders to reduce variability; results may therefore not apply to aflibercept non-responders, participants with thicker retinas, or previously treated populations. The primary endpoint is at 52 weeks, while 4D-150 is a one-time gene therapy intended for multi-year effect; durability beyond 104 weeks and long-term safety are not addressed by the registered outcomes. The statistical analysis sets, handling of intercurrent events, and multiplicity strategy have not been published.

Source: [4D Molecular Therapeutics second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm); [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm); [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/); [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/); [4D Molecular Therapeutics 4FRONT-1 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/02/09/3234480/0/en/4DMT-Completes-Enrollment-for-4FRONT-1-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html); [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and); [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d); [ClinicalTrials.gov NCT06864988](https://clinicaltrials.gov/study/NCT06864988)

<a id="heading-3.1.2"></a>

#### 3.1.2 4FRONT-2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registered study title and purpose

> “A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration”

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.1-2"></a>

###### Main objective in the EU trial record

> “The trial objective is to evaluate the efficacy, safety, and durability of a single intravitreal (IVT) injection of 4D-150 (3 ×10^10 vector genomes [vg]) compared with aflibercept (2mg IVT) every 8 weeks (Q8W) in adults with nAMD.”
> “The primary efficacy objective is to demonstrate non-inferiority of a single injection of 4D-150 to aflibercept (Q8W) in the mean change in BCVA from baseline to Week 52”

Source: [EU Clinical Trials Information System 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public/view/2025-521349-25-00)

<a id="topic-3.1.2.1-3"></a>

###### Primary and key secondary endpoints as described by the sponsor

> “The primary endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity (BCVA) at 52 weeks. The key secondary endpoint is treatment burden reduction comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm over 52 weeks.”

Source: [4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4DMT-Completes-Enrollment-for-4FRONT-2-Global-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Summary: sites and timeline

The ClinicalTrials.gov record for 4FRONT-2 (protocol 4D-150-C004) lists 94 sites in 14 countries: United States (54), Argentina (6), Hungary (6), Japan (5), Australia (4), Germany (3), Latvia (3), Spain (3), United Kingdom (3), Lithuania (2), Singapore (2), Bulgaria (1), Italy (1), and Portugal (1). The EU trial record lists 9 member states (Bulgaria, France, Germany, Hungary, Italy, Latvia, Lithuania, Portugal, and Spain). The study started on 2025-07-22, enrollment was completed in June 2026, randomization of 531 participants was completed in August 2026, and 52-week topline data are expected in the second half of 2027.

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759); [EU Clinical Trials Information System 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public/view/2025-521349-25-00); [4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4DMT-Completes-Enrollment-for-4FRONT-2-Global-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html); [4D Molecular Therapeutics third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm)

<a id="topic-3.1.2.2-2"></a>

###### Study dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2025-07-22” |
| Primary completion (estimated) | “2028-11” |
| Study completion (estimated) | “2029-02” |

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.2-3"></a>

###### Initiation

> “The second Phase 3 trial of 4D-150 in wet AMD, 4FRONT-2, was initiated in June 2025, ahead of schedule.”

Source: [4D Molecular Therapeutics Phase 3 acceleration announcement (2025)](https://www.globenewswire.com/news-release/2025/07/02/3109526/0/en/4DMT-Announces-Accelerated-4D-150-Phase-3-Development-in-Wet-AMD-and-Streamlined-Organization-to-Drive-Late-Stage-Execution.html)

<a id="topic-3.1.2.2-4"></a>

###### Ex-US site activation

> “4FRONT-2, Global Clinical Trial: Ex-U.S. site activation and patient screening accelerating across Europe and Asia-Pacific; enrollment remains on track to be completed in H2 2026, with topline data expected in H2 2027”

Source: [4D Molecular Therapeutics 2026 company update (2026)](https://www.globenewswire.com/news-release/2026/01/07/3214461/0/en/4DMT-Provides-Company-Update-and-Anticipated-Development-Milestones-for-2026.html)

<a id="topic-3.1.2.2-5"></a>

###### Enrollment completion and topline timing

> “4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections”
> “4FRONT-2 52-week topline data is expected in H2 2027”

Source: [4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4DMT-Completes-Enrollment-for-4FRONT-2-Global-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

> “Enrollment completed in June 2026 and randomization completed (N=531) in August 2026; topline data expected in H2 2027”

Source: [4D Molecular Therapeutics third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 3 randomized, double-masked, aflibercept-controlled design

> “4FRONT-2 is a global Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled study of intravitreal 4D-150 in wet AMD that has enrolled both treatment-naïve and recently diagnosed treatment-experienced patients.”
> “Patients in both arms are eligible for supplemental aflibercept injections.”
> “4FRONT-1, the first 4D-150 wet AMD Phase 3 trial, is being conducted in North America evaluating treatment-naïve patients with an otherwise identical design to 4FRONT-2.”

Source: [4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4DMT-Completes-Enrollment-for-4FRONT-2-Global-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

<a id="topic-3.1.2.3-2"></a>

###### Registered design elements

| Design element | Registry record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention model | “Parallel” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.3-3"></a>

###### Planned population mix

| Population | Quoted presentation text |
| --- | --- |
| Region and size | “Global N=480” |
| Treatment-naive share | “≥60% Treatment naïve” |
| Previously treated share | “Up to 40% Previously treated*” |
| Definition of previously treated | “1-4 prior injections, diagnosed within 6 months.” |

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.2.3-4"></a>

###### Aflibercept run-in and response-based randomization

> “Enrolling selected population to reduce variability:”
> “Randomizing strong aflibercept responders only”
> “Durezol® taper (both arms) starting Day -3”

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.2.3-5"></a>

###### Regulatory alignment for global program

> “Study design has been aligned with feedback from U.S. Food and Drug Administration (FDA) under RMAT designation”
> “Alignment ongoing with European Medicines Agency (EMA) under PRIME designation”

Source: [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and)

> “The Amendments support the Company’s planned global regulatory submissions for 4D-150, including by the Company’s recently announced partner, Otsuka Pharmaceutical Co., Ltd., in the Asia-Pacific region, and were driven by the Company’s evolving view of the global commercial opportunity for 4D-150.”

Source: [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Age | “≥50 years of age at time of consent” |
| Treatment history, option 1 | “Treatment naïve, i.e. no prior IVT anti-VEGF therapy OR” |
| Treatment history, option 2 | “Previously treated with no more than 4 IVT anti-VEGF injections due to nAMD and received diagnosis of nAMD no more than 6 months prior to the Screening Visit AND documented evidence of anatomical improvement and visual stability/improvement in response to previous IVT anti-VEGF treatment, as determined by the Investigator” |
| Aflibercept response | “Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center” |
| Visual acuity | “BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit” |
| Retinal thickness | “CST less than or equal to 500 microns in the study eye at screening visit, confirmed by the central reading center” |

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria

> “History of retinal detachment in the study eye”
> “History of or presence of active inflammation in either eye”
> “Any prior or concomitant treatment for MNV or vitreomacular-interface abnormalities, other than allowed prior IVT anti-VEGF in the study eye”
> “History of autoimmune condition that may predispose to the development of uveitis”

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.4-3"></a>

###### Aflibercept run-in response and functional stability required before randomization

> “From Week −5 to Week −1: a ≥ 15% reduction in CST or complete resolution of IRF and/or SRF, determined by SD-OCT and confirmed by the Reading Center”
> “At Day 1: BCVA measurement must not have decreased by 15 ETDRS letters or more compared to BCVA at the Screening visit”

Source: [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)

<a id="topic-3.1.2.4-4"></a>

###### Lesion characteristics and fellow-eye visual acuity required at screening

> “Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT) , in the study eye, at the Screening Visit confirmed by the Reading Center”
> “Total lesion size of 9 disc areas or less (inclusive of blood, fibrosis, atrophy or neovascularization) on FA”
> “MNV component area at least 50% of total lesion size on FA”
> “MNV exudation (i.e. presence of fluid) on SD-OCT”
> “BCVA ≥34 ETDRS letters (~20/200 Snellen equivalent) in the contralateral eye at the Screening Visit”

Source: [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)

<a id="topic-3.1.2.4-5"></a>

###### Exclusions for prior gene therapy, complement inhibitors, brolucizumab, and systemic VEGF inhibitors

> “Any prior gene therapy (ocular or non-ocular) and/or ocular stem cell therapy”
> “Ever received or anticipated to receive IVT complement inhibitors (e.g. pegcetacoplan, avacincaptad pegol) in either eye”
> “Any prior exposure to brolucizumab”
> “Receiving or anticipated to receive a systemic drug that inhibits VEGF pathways, e.g. bevacizumab, sunitinib, pazopanib”

Source: [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)

<a id="topic-3.1.2.4-6"></a>

###### Ocular surgical history and corticosteroid response exclusions

> “History of the following surgeries and procedures: cataract surgery associated with complications, incisional glaucoma surgery (e.g. trabeculectomy), glaucoma tube or shunt placement, pars plana vitrectomy, corneal transplant, sub-macular surgery, retinal detachment surgery, ranibizumab injection implant (Susvimo™), macular laser or extensive panretinal photocoagulation, radiation therapy.”
> “History of steroid-induced ocular hypertension or steroid-induced glaucoma in either eye”

Source: [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)

<a id="topic-3.1.2.4-7"></a>

###### Barrier contraception requirement in the three months after dosing

> “Agree to use a barrier method (e.g. condom) during intercourse for 3 months after Day 1 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period.”

Source: [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Summary: dosing schedule

According to the sponsor's trial schedule, which is shared by 4FRONT-1 and 4FRONT-2, participants in both arms receive aflibercept 2 mg at Weeks -5 and -1 and are randomized on Day 1, when the 4D-150 arm receives a single intravitreal injection of 4D-150 3E10 vg/eye and the aflibercept arm receives a sham injection. Both arms receive aflibercept at Week 4. From Week 12 through Week 52 the aflibercept arm receives aflibercept every 8 weeks and the 4D-150 arm receives sham injections at the same visits. Both arms receive a Durezol (difluprednate) taper starting on Day -3 and are eligible for supplemental aflibercept when protocol-defined disease activity criteria are met.

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d); [4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4DMT-Completes-Enrollment-for-4FRONT-2-Global-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html)

<a id="topic-3.1.2.5-2"></a>

###### Treatment arms

| Arm | Quoted registry description |
| --- | --- |
| 4D-150 IVT (3E10 vg/eye), experimental | “If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1” |
| Aflibercept (AFLB) 2 mg IVT, active comparator | “Eylea (aflibercept) will be administered at applicable visits” |

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.5-3"></a>

###### Supplemental aflibercept criteria

| Criterion | Quoted presentation text |
| --- | --- |
| Arms eligible | “Supplemental Aflibercept Criteria (Both arms)” |
| BCVA reference value | “BCVA: Average of Week 4 & 8” |
| CST reference value | “CST: Week 8” |
| Vision and anatomy | “Vision & Anatomy: ≥5 letter loss in BCVA AND ≥50 µm increase in CST” |
| Vision | “Vision: ≥10 letter loss in BCVA” |
| Anatomy | “Anatomy: ≥100 µm increase in CST” |
| Hemorrhage | “New vision-threatening hemorrhage” |
| Investigator discretion | “PI discretion not allowed.” |

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.2.5-4"></a>

###### Dose selection

> “The Phase 2b trial enrolled 45 patients at two dose levels of a single intravitreal dose of 4D-150 (3E10 and 1E10 vg/eye); 3E10 vg/eye was chosen as the dose for the 4FRONT Phase 3 clinical trials”

Source: [4D Molecular Therapeutics Form 8-K PRISM 2-year data (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Best Corrected Visual Acuity as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Registry record | Time frame |
| --- | --- | --- |
| Primary | “Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52” | “52 Weeks” |
| Secondary | “Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104” | “104 Weeks” |
| Secondary | “Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104” | “104 Weeks” |
| Secondary | “Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm” | “104 Weeks” |
| Secondary | “Mean change from baseline in Central Subfield Thickness (CST) over time through Weeks 52 and 104” | “104 Weeks” |
| Secondary | “Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104” | “104 Weeks” |

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.6.1-2"></a>

###### Noninferiority margins: FDA and ex-US regulators

> “As previously disclosed, the 4FRONT Trials were initiated to provide >90% power for a primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks with a margin of 4.5 letters (in accordance with U.S. Food and Drug Administration guidance).”
> “The increase in target enrollment in the 4FRONT Trials is designed to provide approximately 90% power with a noninferiority margin of approximately 4 letters outside of FDA jurisdiction such as Japan Pharmaceuticals and Medical Devices Agency and European Medicines Agency.”

Source: [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm)

> “Robustly powered for global approval standards (~4 letter noninferiority margin)”

Source: [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d)

<a id="topic-3.1.2.6.1-3"></a>

###### FDA guidance on selecting a noninferiority margin

> “It is therefore usual in NI studies to choose a smaller margin (M2) that reflects the largest loss of effect that would be clinically acceptable.”

Source: [FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016)](https://www.fda.gov/media/78504/download)

<a id="topic-3.1.2.6.1-4"></a>

###### Derivation of a 4-letter margin from historical anti-VEGF trials

> “The 4-letter non-inferiority margin preserves approximately 70% of the least estimated benefit of ranibizumab over sham control in the MARINA study.”
> “From a clinical perspective, the non-inferiority margin should be fewer than 5 letters, given that a loss of 5 letters (one ETDRS line) between treatments would be considered clinically relevant.”

Source: [Hoffmann-La Roche TENAYA protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/87/NCT03823287/Prot_000.pdf)

<a id="topic-3.1.2.6.1-5"></a>

###### A 4.5-letter margin in a prior nAMD phase 3 trial versus aflibercept

> “The maximum clinically acceptable true difference between KSI-301 and aflibercept among wAMD patients to be considered non-inferior is 4.5 ETDRS letters, i.e. the non-inferiority margin (NI) is 4.5 letters.”

Source: [Kodiak Sciences DAYLIGHT statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04964089/SAP_001.pdf)

<a id="topic-3.1.2.6.1-6"></a>

###### Primary endpoint and time to first aflibercept injection as recorded in the EU register

| Outcome | EU trial record |
| --- | --- |
| Primary endpoint | “Mean change from baseline in BCVA ETDRS letter score at Week 52” |
| Secondary endpoint not listed on ClinicalTrials.gov | “Time to first aflibercept injection after Week 4 in the 4D-150 arm” |

Source: [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)

<a id="topic-3.1.2.6.1-7"></a>

###### Certification of visual acuity measurement for the primary endpoint

> “Best corrected visual acuity (BCVA) certification, Low Luminance visual acuity, manifest refraction, and lane certifications”

Source: [EU CTIS 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2025-521349-25-00)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment: registry record

| Enrollment type | Participants |
| --- | --- |
| Estimated | “480” |

Source: [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759)

<a id="topic-3.1.2.7.1-2"></a>

###### Sample size and power

> “Target enrollment per study is 480 patients randomized 1:1 to 4D-150 or the aflibercept comparator arm, providing approximately 90% power with a noninferiority margin of 4 letters as aligned with the Japan Pharmaceuticals and Medical Devices Agency and EMA and over 90% power with a noninferiority margin of 4.5 letters per FDA guidance.”

Source: [4D Molecular Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm)

<a id="topic-3.1.2.7.1-3"></a>

###### Protocol amendment increasing target enrollment

> “On December 10, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) announced its intention to implement protocol amendments (the “Amendments”) to the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials of 4D-150 in wet AMD (the “4FRONT Trials”) to increase target enrollment from 400 to 480 patients per trial.”

Source: [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm)

<a id="topic-3.1.2.7.1-4"></a>

###### Randomized participants

> “We completed enrollment for 4FRONT-2 in June 2026 with 531 patients randomized.”

Source: [4D Molecular Therapeutics third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526458477/fdmt-20260930.htm)

<a id="topic-3.1.2.7.1-5"></a>

###### Analyzed population

No evidence found.

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

No results have been reported as of November 2026; enrollment was completed in June 2026, randomization of 531 participants was completed in August 2026, and 52-week topline data are expected in the second half of 2027 (registry primary completion estimated November 2028). The design matches 4FRONT-1 apart from population and geography, so the limitations of 4FRONT-1 apply: noninferiority testing with a 4.5-letter FDA margin and an approximately 4-letter margin for EMA and PMDA, supplemental aflibercept allowed in both arms under criteria that exclude investigator discretion, randomization restricted to participants with a documented anatomic response to aflibercept during the run-in, and a 52-week primary endpoint for a one-time gene therapy. Up to 40% of participants may be previously treated (1 to 4 prior anti-VEGF injections and diagnosis within 6 months), so results will not apply to patients with longer disease duration or extensive prior treatment. Because 4FRONT-2 enrolled across 14 countries, including sites in Europe, Latin America, Japan, Singapore, and Australia, regional differences in practice may add variability, and the EU trial record excludes women of child-bearing potential. The statistical analysis sets, handling of intercurrent events, and multiplicity strategy have not been published.

Source: [4D Molecular Therapeutics 4FRONT-2 enrollment announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4DMT-Completes-Enrollment-for-4FRONT-2-Global-Phase-3-Clinical-Trial-of-4D-150-in-Wet-AMD.html); [ClinicalTrials.gov NCT07064759](https://clinicaltrials.gov/study/NCT07064759); [4D Molecular Therapeutics Form 8-K protocol amendment (2025)](https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm); [4D Molecular Therapeutics corporate presentation (2026)](https://ir.4dmoleculartherapeutics.com/static-files/9990820a-994e-49f6-b8c8-1978eb79b25d); [EU Clinical Trials Information System 2025-521349-25-00](https://euclinicaltrials.eu/ctis-public/view/2025-521349-25-00); [4D Molecular Therapeutics third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm)

<a id="heading-3.1.3"></a>

#### 3.1.3 PRISM Phase 2a Dose Expansion

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registered trial objective

> “Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.3.1-2"></a>

###### Objective of the randomized dose expansion analysis

> “Here we report initial results from the PRISM randomized phase 2 dose expansion study”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry dates for the overall PRISM trial

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2021-12-09” |
| Primary completion (estimated) | “2027-03” |
| Study completion (estimated) | “2031-01” |

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.3.2-2"></a>

###### Study sites

> “PRISM is a multicenter, Phase 1/2 open-label dose exploration and randomized dose expansion study evaluating 4D-150 (NCT05197270)”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

> “Barnet Delaney Perkins Eye Center”
> “Emanuelli Research and Development Center, LLC”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Randomized, controlled, outcome assessor-masked dose expansion versus aflibercept

> “In Dose Expansion, subjects (n=50) will be randomized to receive one of 2 dose levels of 4D-150 (n=20 for each dose level) based on results from Dose Escalation, or aflibercept (n=10).”
> “During Dose Expansion, outcome assessors will be masked to treatment assignment. Other site personnel (including investigator) and subjects will be unmasked to treatment assignment but will be masked to 4D-150 dose level.”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “Powered to detect difference in anti-VEGF injections compared to aflibercept; study participants and site personnel masked to 4D-150 dose (treatment assignment to 4D-150 vs aflibercept not masked).”

Source: [Khanani (2024a)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis_PRISM-Phase-2-Initial-Results.pdf)

<a id="topic-3.1.3.3-2"></a>

###### Follow-up duration and long-term follow-up

> “After receiving one time administration of 4D-150 by intravitreal injection (IVT), subjects will undergo assessments at monthly intervals for 24 months to assess safety and efficacy outcomes. Only subjects that received 4D-150 will then enter a long-term follow-up (LTFU) period to assess long-term safety of 4D-150 gene therapy and duration of clinical activity through year 5 (60 months).”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.3.3-3"></a>

###### Position of the dose expansion within the PRISM cohorts

> “The trial consists of Dose Escalation, Dose Expansion, Steroid Optimization, and Population Extension Cohorts.”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “The Dose Expansion cohort of the PRISM study is a randomized, controlled Phase 2 clinical trial evaluating 4D-150 in previously treated wet AMD patients with severe disease activity (≥325 µm central subfield thickness (CST) measured by optical coherence tomography (OCT) and presence of subretinal or intraretinal fluid) and a high treatment burden (≥6 anti-VEGF injections in the prior 12 months).”

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Registered inclusion criteria for the main trial

> “Diagnosed with CNV secondary to AMD (confirmed by reading center)”
> “Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye AND has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening:”
> “Medical records available to document history of anti-VEGF therapy (dates, drugs, and dosage) for a minimum of 12 months prior to Screening”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.3.4-2"></a>

###### Key eligibility criteria for the dose expansion cohort

| Criterion | Quoted poster text |
| --- | --- |
| Diagnosis | “Study eye macular neovascularization secondary to AMD” |
| Visual acuity | “Best corrected visual acuity (BCVA) of 34–83 letters (Snellen 20/200–20/25)” |
| Prior treatment | “≥6 anti-VEGF injections during the prior 12 months” |

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Randomized treatment arms

> “Enrolled patients were randomized 2:2:1 to receive a single high (3E10 vg/eye) or low (1E10 vg/eye) intravitreal dose of 4D-150 or intravitreal aflibercept 2 mg every 8 weeks (control).”

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)

| Arm | Quoted registry description |
| --- | --- |
| 4D-150 Dose Expansion Dose 1 and Dose 2 | “4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.” |
| 4D-150 Dose Expansion Control | “Aflibercept at a fixed regimen will be administered.” |
| Investigational product | “4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept” |

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.3.5-2"></a>

###### Aflibercept run-in and prophylactic corticosteroid

> “Note: Day -7 aflibercept will be administered ≥ 4 weeks from last IVT anti-VEGF”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “Scheduled 20-week corticosteroid taper (4D-150 groups).”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="topic-3.1.3.5-3"></a>

###### Supplemental aflibercept injection criteria

> “BCVA: Loss of ≥10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters from the average of the Day –7 and Day –1 values attributable to intra- or subretinal fluid, or”
> “CST: ≥75 μm increase from the average of the Day –7 and Day –1 values, or”
> “New vision-threatening hemorrhage due to nAMD”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Time frame |
| --- | --- |
| “Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parameters” | “52 weeks” |
| “Time to receiving the first supplemental aflibercept injection” | “52 weeks” |
| “Percentage of subjects requiring supplemental aflibercept injections over 52 weeks” | “52 weeks” |
| “Number of supplemental aflibercept injections over 52 weeks” | “52 weeks” |
| “Change from baseline in BCVA over time (up to 52 weeks) as assessed using the ETDRS Visual Acuity Chart” | “52 weeks” |
| “Change from baseline in central subfield thickness (CST) over time (up to 52 weeks) measured by spectral domain optical coherence tomography (SD-OCT)” | “52 weeks” |
| “Percent Change in Annualized Mean Number of anti-VEGF IVT injections before and after the 4D-150 injection” | “Before and after the 4D-150 injection (or Day 1 for the aflibercept only arm)” |

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.3.6.1-2"></a>

###### Study outcomes as presented for the dose expansion

> “Primary: Incidence and severity of adverse events”
> “Secondary: Annualized number of supplemental anti-VEGF injections, change from baseline in BCVA, and change from baseline in CST”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="topic-3.1.3.6.1-3"></a>

###### Rationale for treatment burden as the key activity measure

> “Repeated injections of anti-vascular endothelial growth factor (VEGF) agents slow vision loss in the majority of treatment-compliant patients; however, many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned and enrolled participants

| Item | Quoted text |
| --- | --- |
| Planned dose expansion enrollment (registry) | “In Dose Expansion, subjects (n=50) will be randomized” |
| Estimated total PRISM enrollment (registry) | “215” |

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “The trial enrolled 51 patients with severe disease activity and treatment burden:”

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)

<a id="topic-3.1.3.7.1-2"></a>

###### Participants included in the pooled Phase 1/2a analyses at the planned Phase 3 dose

> “Phase 1/2a (n=24, all patients have reached year 2): Severe, recalcitrant disease activity”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Mixed-effect model for visual acuity and retinal thickness

> “Baseline=Day -7. Adjusted mean, difference in adjusted mean, and 95% CI estimated from a mixed–effect model (MMRM) for repeated measures including observed data (weeks 4–24) without imputation of missing values.”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Kaplan-Meier estimates for supplemental injection endpoints at week 52

> “Based on Kaplan-Meier method for calculating endpoint with follow-up through 52 weeks (Phase 1/2a).”

Source: [Khanani (2024d)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_EURETINA-2024_PRISM_Presentation_9_17_2459.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### Comparator for pooled Phase 1/2a treatment burden reduction

> “Compared to mean injections in prior 12 months”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="topic-3.1.3.7.2-4"></a>

###### Preliminary Phase 3 eligibility subgroup

> “Participants excluded based on BCVA <40 or >78 ETDRS letters (n=6), CST >500 mm (n=1), or both BCVA <40 or >78 ETDRS letters and CST >500 mm (n=1).”

Source: [Khanani (2024a)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis_PRISM-Phase-2-Initial-Results.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Early terminations and censoring through week 52

> “Early termination (death unrelated to study treatment), one of whom had missing data from Week 36 until death at Week 57.”
> “Participant censored for supplemental injection assessment owing to protocol deviation (lost to follow up for >3 months after entering a nursing home).”

Source: [Khanani (2024d)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_EURETINA-2024_PRISM_Presentation_9_17_2459.pdf)

<a id="topic-3.1.3.8.1-2"></a>

###### Corticosteroid taper completion at the 24-week analysis

> “97% (38 of 39) completed the 20-week topical corticosteroid taper on schedule; no participant restarted steroids during up to 48 weeks of follow up”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics and baseline disease characteristics by arm

| Characteristic | 4D-150 3E10 vg/eye (N=20) | 4D-150 1E10 vg/eye (N=21) | Aflibercept 2 mg (N=10) | Total (N=51) |
| --- | --- | --- | --- | --- |
| Mean ±SD age, years | “77 ±8.0” | “77 ±8.6” | “80 ±4.1” | “77 ±7.7” |
| Female, n (%) | “8 (40)” | “11 (52)” | “5 (50)” | “24 (47)” |
| Mean ±SD time since diagnosis, years | “4.0 ±3.0” | “2.9 ±2.2” | “1.9 ±1.5” | “3.1 ±2.5” |
| Mean ±SD BCVA, ETDRS letters | “68 ±11.3” | “71 ±12.4” | “71 ±13.2” | “70 ±11.9” |
| Mean ±SD central subfield thickness | “429 ±89.3” | “465 ±114.1” | “419 ±64.3” | “442 ±96.9” |
| Mean ±SD actual injections in prior 12 months | “9.9 ±2.4” | “9.4 ±2.1” | “9.3 ±0.9” | “9.6 ±2.0” |

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="topic-3.1.3.8.2-2"></a>

###### Summary of disease severity at baseline

> “Baseline characteristics consistent with severe disease activity (mean CST, 442 mm) and high treatment burden (mean actual injections in prior 12 months, 9.6)”

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="topic-3.1.3.8.2-3"></a>

###### Race and prior annualized injection rate by arm

| Characteristic | 4D-150 3E10 vg/eye (N=20) | 4D-150 1E10 vg/eye (N=21) | Aflibercept 2 mg Q8W (N=10) |
| --- | --- | --- | --- |
| White, n (%) | “18 (90)” | “21 (100)” | “9 (90)” |
| Mean prior annualized injection rate | “10.0” | “9.9” | “9.0” |

Source: [Eichenbaum (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Retina-Society_Eichenbaum_PRISM-Phase-2-Interim-Results_vF.pdf)

> “*Includes Day -7 AFLB injection.”

Source: [Eichenbaum (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Retina-Society_Eichenbaum_PRISM-Phase-2-Interim-Results_vF.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Summary: randomized 24-week and pooled long-term results

At the 24-week landmark (data cutoff January 19, 2024), the 3E10 vg/eye arm (n=20) had an 89% reduction in annualized anti-VEGF injection rate, 84% of participants received 0 or 1 supplemental injection, and 63% were injection-free; corresponding values in the 1E10 vg/eye arm (n=21) were 85%, 90%, and 50%. The average week 20 and 24 adjusted mean BCVA difference versus aflibercept 2 mg every 8 weeks (n=10) was -1.8 letters (95% CI -7.6 to 4.1) for 3E10 vg/eye and +1.8 letters (95% CI -3.8 to 7.4) for 1E10 vg/eye; confidence intervals include zero, and the study was powered for injection differences, not visual acuity. In the pooled Phase 1/2a 3E10 vg/eye population (n=24), treatment burden reduction versus the prior 12 months was 83% through year 1 and 79% through year 2 (data cutoff August 22, 2025), with a mean of 1.2 supplemental injections per participant in the 18 to 24 month interval.

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html); [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf); [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="topic-3.1.3.8.3-2"></a>

###### Treatment burden at week 24 by 4D-150 dose

| Outcome | 4D-150 3E10 vg/eye and 1E10 vg/eye |
| --- | --- |
| Annualized anti-VEGF injection rate | “89% and 85% reduction in annualized anti-VEGF injection rates in the high (3E10 vg/eye) and low (1E10 vg/eye) 4D-150 dose arms, respectively” |
| 0 or 1 supplemental injection | “84% and 90% of patients received 0 or 1 supplemental aflibercept injection in the high and low 4D-150 dose arms, respectively” |
| Injection-free | “63% and 50% of patients were supplemental aflibercept injection-free in the high and low 4D-150 dose arms, respectively” |

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)

<a id="topic-3.1.3.8.3-3"></a>

###### BCVA and CST versus aflibercept at weeks 20 and 24

| Comparison versus aflibercept 2 mg Q8W | Week 20 | Week 24 | Average of weeks 20 and 24 |
| --- | --- | --- | --- |
| BCVA, 4D-150 3E10 vg/eye (ETDRS letters) | “–1.0 (–7.2, 5.3)” | “–2.6 (–9.3, 4.2)” | “–1.8 (–7.6, 4.1)” |
| BCVA, 4D-150 1E10 vg/eye (ETDRS letters) | “2.3 (–3.6, 8.3)” | “1.3 (–5.2, 7.8)” | “+1.8 (–3.8, 7.4)” |
| CST, 4D-150 3E10 vg/eye (µm) | “–9.3 (–97.9, 79.3)” | “–7.3 (–101, 86.2)” | “–8.3 (–92.6, 76.0)” |
| CST, 4D-150 1E10 vg/eye (µm) | “38.1 (–48.9, 125.2)” | “21.7 (–70.4, 113.8)” | “+29.9 (–53.0, 112.8)” |

Source: [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf)

<a id="topic-3.1.3.8.3-4"></a>

###### Preliminary Phase 3-eligible subgroup at week 24

> “Application of preliminary Phase 3 eligibility criteria for BCVA and CST to the PRISM Dose Expansion Phase 2 study (16 of 20 in high dose 4D-150 arm and 6 of 10 in aflibercept arm met criteria) demonstrated: BCVA: +3.3 letters favoring high dose 4D-150 vs. aflibercept CST: –99.0 µm favoring high dose 4D-150 vs. aflibercept Anti-VEGF treatment burden: 90% reduction in annualized injection rate (88% received 0 or 1 injection, 63% were injection-free)”

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)

<a id="topic-3.1.3.8.3-5"></a>

###### Supplemental injection-free subgroup at week 24

> “Stable visual acuity observed through Week 24 in both 4D-150 dose groups (n=22 injection-free patients); BCVA equal to or numerically higher than bimonthly aflibercept (n=10 patients) at all six time points through Week 24”
> “The average mean change from baseline in CST at Weeks 20 and 24 was -52.2 mm in the 3E10 vg/eye group and -21.4 in the aflibercept group (mean difference, -30.8 mm)”

Source: [4D Molecular Therapeutics PRISM injection-free subgroup analyses announcement (2024)](https://www.globenewswire.com/news-release/2024/06/08/2895689/0/en/4DMT-Presents-Injection-Free-Subgroup-Analyses-from-4D-150-Phase-2-PRISM-Randomized-Dose-Expansion-Cohort-in-Wet-AMD-Patients-with-Severe-Disease-Activity-High-Treatment-Burden-at-.html)

<a id="topic-3.1.3.8.3-6"></a>

###### Pooled Phase 1/2a treatment burden through week 52

> “Phase 1/2a Severe (n=24, through 52 weeks): 83% overall reduction in annualized injections 52% received 0 or 1 injection* 44% injection-free*”

Source: [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and)

> “2 control arm patients received supplemental injections”

Source: [Khanani (2024d)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_EURETINA-2024_PRISM_Presentation_9_17_2459.pdf)

<a id="topic-3.1.3.8.3-7"></a>

###### Pooled Phase 1/2a treatment burden and dose response through year 2

> “Phase 1/2a2: Severe, Recalcitrant 83% 79%”
> “Phase 1/2a: Severe, Recalcitrant 0.5 1.3 1.2 1.2”
> “Phase 1/2a (at 2 years): 79% vs. 69%”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="topic-3.1.3.8.3-8"></a>

###### Visual acuity and anatomy through year 2

> “Consistent maintenance of visual acuity as measured by best corrected visual acuity through up to 2 years”
> “Consistent control of retinal anatomy (central subfield thickness as measured on optical coherence tomography), with fewer fluctuations through up to 2 years”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

> “79% reduction in a recalcitrant population”

Source: [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)

<a id="topic-3.1.3.8.3-9"></a>

###### Visual acuity and retinal thickness versus aflibercept by supplemental injection status

| Subgroup and dose | Group size as labeled | Average BCVA difference versus aflibercept (95% CI), ETDRS letters | Average CST difference versus aflibercept (95% CI), µm |
| --- | --- | --- | --- |
| Supplemental injection-free, 3E10 vg/eye | “4D-150 3x1010 vg/eye (n=12)” | “+0.4 (–5.2, 6.1)” | “–30.8 (–125, 63.2)” |
| Supplemental injection-free, 1E10 vg/eye | “4D-150 1x1010 vg/eye (n=10)” | “+4.5 (–1.2, 10.3)” | “+8.7 (–90.3, 107.7)” |
| Supplemental injection received, 3E10 vg/eye | “3E10: Injected post 4D-150 (n=7)” | “+1.5 (–5.7, 8.6)” | “+4.7 (–115, 124.0)” |
| Supplemental injection received, 1E10 vg/eye | “1E10: Injected post 4D-150 (n=10)” | “+1.3 (–4.3, 6.9)” | “+54.9 (–42.3, 152.0)” |

Source: [Danzig (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Clinical-Trials-at-the-Summit_Danzig_PRISM-24-week-Results_vFinal_6June2024.pdf)

> “Excludes participants (n=1 per dose group) with missing data due to early termination.”

Source: [Danzig (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Clinical-Trials-at-the-Summit_Danzig_PRISM-24-week-Results_vFinal_6June2024.pdf)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Safety at the 24-week landmark analysis

> “No significant intraocular inflammation High dose: None 97% (38 of 39 pts) completed 20-week prophylactic topical corticosteroid taper on schedule Low dose: Single eye at week 16 had 1+ anterior mixed (pigmented & white blood) cells, resolved by next visit and completed prophylactic topical corticosteroid taper by week 26 All patients currently off steroids No 4D-150–related serious adverse events (SAEs) or study eye SAEs No hypotony, endophthalmitis, retinal vasculitis, choroidal effusions, or retinal artery occlusions”

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)

<a id="topic-3.1.3.8.5-2"></a>

###### Safety across all Phase 3-dose participants through up to 3.5 years

> “As previously reported, within approximately the first 6 months (28 weeks) post-4D-150 dosing, 2.8% (2 of 71) of patients had 4D-150-related 1+ (mild) intraocular inflammation (IOI) (SUN/NEI scales), which were transient 1+ vitreous cells noted at a single timepoint Following the first 28 weeks post-4D-150 dosing, no new cases of inflammation with approximately 1.5 to more than 3.5 years of follow-up on all patients as of the data cutoff 99% (70 of 71) completed steroid prophylaxis taper on schedule 99% (70 of 71) remained completely off steroids No 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis or choroidal effusions observed to date”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The dose expansion is a small randomized Phase 2 study of 51 participants (20, 21, and 10 per arm) in which participants and investigators were not masked to 4D-150 versus aflibercept assignment and only outcome assessors were masked; it was powered for differences in anti-VEGF injections, not for visual acuity, and the BCVA and CST differences versus aflibercept have confidence intervals that include zero (for example, BCVA -1.8 letters, 95% CI -7.6 to 4.1, at 3E10 vg/eye). Comparative results versus the aflibercept arm have been reported only through week 24; later results pool the 3E10 vg/eye Phase 1 and Phase 2a participants (n=24) as a single-arm cohort, with treatment burden reduction calculated against each participant's injections in the prior 12 months rather than against a concurrent control. Two control arm participants received supplemental injections. The population had severe disease and a high prior treatment burden (mean CST 442 µm; 9.6 injections in the prior 12 months), which differs from the treatment-naive or recently diagnosed population of the 4FRONT Phase 3 trials. The Phase 3-eligible subgroup BCVA difference was reported as +3.3 letters in the company announcement, whereas the congress slides for the same subgroup show +2.4 letters. Results are available only from company announcements and congress presentations; no peer-reviewed full publication was identified, and no patient-reported outcomes have been reported.

Source: [Khanani (2024a)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis_PRISM-Phase-2-Initial-Results.pdf); [Khanani et al. (2024c)](https://4dmoleculartherapeutics.com/wp-content/uploads/Poster_ARVO-2024_PRISM-Dose-Expansion-24-Weeks_Khanani_Production.pdf); [Khanani (2024d)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_EURETINA-2024_PRISM_Presentation_9_17_2459.pdf); [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html); [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html); [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="heading-3.1.4"></a>

#### 3.1.4 PRISM Phase 2b Population Extension

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Registered trial objective

> “Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.4.1-2"></a>

###### Objective of the Population Extension cohort

> “The cohort evaluated 4D-150 in wet AMD patients with broad disease activity (no minimum or maximum central subfield thickness (CST)) and prior anti-VEGF treatment (1-6 anti-VEGF injections in the prior 12 months).”

Source: [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry dates for the overall PRISM trial

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2021-12-09” |
| Primary completion (estimated) | “2027-03” |
| Study completion (estimated) | “2031-01” |

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.4.2-2"></a>

###### Enrollment completion and data cutoffs

> “Enrollment completed ahead of schedule in Phase 2 PRISM Population Extension cohort evaluating 4D-150 in wet AMD patients with broader disease severity (no minimum CST) and lower treatment burden (1-6 anti-VEGF injections in prior 12 months, ≥1 in last 12 weeks), with 32 patients dosed with 3E10 or 1E10 vg/eye of 4D-150”

Source: [4D Molecular Therapeutics PRISM Dose Expansion 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/02/03/2823166/0/en/4DMT-Presents-Positive-Interim-Data-from-Randomized-Phase-2-PRISM-Clinical-Trial-of-Intravitreal-4D-150-Demonstrating-Favorable-Tolerability-Clinical-Activity-in-Wet-AMD.html)

> “2-Year Data from PRISM Phase 2b Clinical Trial (Data Cutoff May 18, 2026):”

Source: [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Open-label, sequentially assigned, two-dose cohort

> “In Steroid Optimization (n=up to 96) and Population Extension (n=up to 45) Cohorts, subjects will be assigned sequentially to receive 4D-150 at doses cleared by the DSMC.”
> “Steroid Optimization and Population Extension will be open-label.”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “Includes participants in the alternative steroid cohort who enrolled under the Population Extension eligibility criteria (n=13).”

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="topic-3.1.4.3-2"></a>

###### Registered substudies and long-term follow-up

> “Eligible subjects who received 4D-150 in the study eye may participate in a sub-study to evaluate one-time IVT administration of 4D-150 to the contralateral ("fellow") eye.”
> “In both sub-studies, subjects will undergo regular assessments to assess safety and tolerability through Week 52 and then will enter long-term follow-up for safety evaluation through year 5 (60 months).”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.4.3-3"></a>

###### Recently diagnosed subgroup

> “The Phase 2b cohort subgroup comprised recently diagnosed patients (diagnosed within 6 months, n=15 at 3E10 vg/eye), which is most comparable to the population enrolled in the 4FRONT Phase 3 clinical trials”

Source: [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Key inclusion criteria for the Population Extension cohort

| Criterion | Quoted slide text |
| --- | --- |
| Prior anti-VEGF injections | “1–6 in prior 12 m (≥1 last 12 weeks)” |
| CST at screening | “No minimum or maximum” |
| BCVA at screening | “34–83 ETDRS letters” |

Source: [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)

<a id="topic-3.1.4.4-2"></a>

###### Registered inclusion criteria for the main trial

> “Diagnosed with CNV secondary to AMD (confirmed by reading center)”
> “Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye AND has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening:”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dose arms

> “The Phase 2b trial enrolled 45 patients at two dose levels of a single intravitreal dose of 4D-150 (3E10 and 1E10 vg/eye); 3E10 vg/eye was chosen as the dose for the 4FRONT Phase 3 clinical trials”

Source: [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html)

<a id="topic-3.1.4.5-2"></a>

###### Scheduled aflibercept loading doses

> “Aflibercept 2mg dosed at Day -7 and Day 28. 4D-150 dosed at Day 0.”

Source: [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="topic-3.1.4.5-3"></a>

###### Prophylactic corticosteroid regimens

> “Participants received one of the following: (a) difluprednate ophthalmic emulsion, (b) triamcinolone acetonide with prednisolone taper, or (c) dexamethasone .”

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

> “Prophylactic corticosteroid (~20 weeks)”

Source: [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="topic-3.1.4.5-4"></a>

###### Supplemental aflibercept injection criteria

> “BCVA:  Loss of ≥10 letters from the average of the Day -7 and Day 1 values attributable to intraretinal or subretinal fluid”
> “CST:  Increase ≥75 μm from the average of the Day -7 and Day 1 values”
> “New vision-threatening hemorrhage due to wet AMD per investigator”

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary outcome

| Outcome | Time frame |
| --- | --- |
| “Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parameters” | “52 weeks” |

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.4.6.1-2"></a>

###### Key endpoints presented for the Population Extension cohort

> “Safety and tolerability”
> “Annualized anti-VEGF injection rate”
> “% requiring supplemental aflibercept injection”
> “Change from baseline in BCVA and CST”

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="topic-3.1.4.6.1-3"></a>

###### Treatment burden benchmark against projected on-label aflibercept

> “Projection based on approved dosing schedule for aflibercept in wet AMD after loading doses.”

Source: [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="topic-3.1.4.6.1-4"></a>

###### Rationale for endpoint selection

No evidence found.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned and enrolled participants

> “In Steroid Optimization (n=up to 96) and Population Extension (n=up to 45) Cohorts, subjects will be assigned sequentially to receive 4D-150 at doses cleared by the DSMC.”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “The trial enrolled 45 patients at two dose level arms of 4D-150: 30 at 3E10 vg/eye (planned Phase 3 dose) 15 at 1E10 vg/eye (low dose control)”

Source: [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)

<a id="topic-3.1.4.7.1-2"></a>

###### Participants analyzed at 2 years

> “3E10 vg/eye (n=30)”
> “1E10 vg/eye (n=15)”
> “3E10 vg/eye (n=15)”
> “1E10 vg/eye (n=11)”

Source: [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Mean cumulative function for supplemental injections

> “MCF, mean cumulative function derived from a single-arm Cox proportional hazard regression model. Projection based on approved dosing schedule for aflibercept in wet AMD after loading doses.”

Source: [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)

<a id="topic-3.1.4.7.2-2"></a>

###### Handling of missing and confounded BCVA assessments at week 52

> “Best available data as of January 15, 2025. BCVA shown at each timepoint includes data for all participants except for missed visits (n=5 patients) or confounded assessments due to confounded by cataract or surgery (n=1 at 3 timepoints and n=1 at 7 timepoints);”

Source: [Pieramici (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis-2025-PRISM-Ph2b-Dante_08-Feb-2025_vFF-1.pdf)

<a id="topic-3.1.4.7.2-3"></a>

###### Mixed-effect model at the 24-week analysis

> “Adjusted mean and 95% CI estimated from a mixed–effect model for repeated measures (MMRM) including observed data (weeks 4-24) without imputing missing values.”

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="topic-3.1.4.7.2-4"></a>

###### Kaplan-Meier estimates at the September 2024 data cutoff

> “Based on Kaplan-Meier method for calculating endpoint with variable follow-up through 32-52 weeks.”

Source: [Khanani (2024d)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_EURETINA-2024_PRISM_Presentation_9_17_2459.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Follow-up status

> “Phase 2b (n=30, all patients reached year 1.5): Broad disease activity”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="topic-3.1.4.8.1-2"></a>

###### Corticosteroid regimen completion at week 24

> “30/30 completed steroid regimen on schedule”
> “13/15 completed steroid regimen on schedule”
> “2/15 on steroids at week 24 (1 restarted)”

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="topic-3.1.4.8.1-3"></a>

###### Discontinuations

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Demographics and baseline disease characteristics by dose

| Characteristic | 4D-150 3E10 vg/eye (N=30) | 4D-150 1E10 vg/eye (N=15) | Total (N=45) |
| --- | --- | --- | --- |
| Mean ±SD age, years | “77 ±7.7” | “78 ±8.6” | “77 ±7.9” |
| Female, n (%) | “20 (67)” | “6 (40)” | “26 (58)” |
| Mean ±SD BCVA, ETDRS letters | “71 ±9.9” | “73 ±8.8” | “72 ±9.5” |
| Mean ±SD central subfield thickness | “336 ±135.0” | “314 ±70.8” | “329 ±117.1” |
| Mean ±SD time since diagnosis, years | “1.8 ±3.5” | “0.7 ±0.9” | “1.4 ±2.9” |
| Mean ±SD actual anti-VEGF injections in prior 12 months | “4.4 ±2.0” | “4.3 ±2.1” | “4.4 ±2.0” |

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="topic-3.1.4.8.2-2"></a>

###### Recently diagnosed subgroup at baseline

| Characteristic | Phase 2b recently diagnosed subgroup, 3E10 vg/eye |
| --- | --- |
| Mean injections in last 12 months | “2.7” |
| Mean CST | “304 µm” |
| Mean time since diagnosis | “2.4 months” |

Source: [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Summary: treatment burden, visual acuity, and anatomy through 2 years

At the 2-year analysis (data cutoff May 18, 2026), participants receiving 3E10 vg/eye (n=30) received a mean of 2.7 supplemental injections, a 78% reduction versus 12.0 injections projected for on-label aflibercept 2 mg every 8 weeks, and 46% were injection-free; the 1E10 vg/eye arm (n=15) received a mean of 3.7 injections (69% reduction). In the recently diagnosed subgroup at 3E10 vg/eye (n=15), the mean was 1.6 injections (87% reduction) and 66% were injection-free. The reduction at 3E10 vg/eye declined from 83% at 52 weeks (0.97 mean injections, 57% injection-free) and 82% at 1.5 years to 78% at 2 years. Mean BCVA change at week 52 was +2.2 letters with censoring of confounded assessments and +1.0 letter without censoring; mean CST change was -11 µm. At 2 years, BCVA and CST were described as maintained, with numerical values shown only in figures.

Source: [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html); [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf); [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf); [4D Molecular Therapeutics PRISM Phase 2b 52-week results announcement (2025)](https://www.globenewswire.com/news-release/2025/02/08/3023106/0/en/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-durability-data-supporting-4d-150-4front-global-registration-program.html); [Pieramici (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis-2025-PRISM-Ph2b-Dante_08-Feb-2025_vFF-1.pdf)

<a id="topic-3.1.4.8.3-2"></a>

###### Treatment burden through 2 years

> “Overall cohort: 78% overall treatment burden reduction (2.7 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)”
> “Recently diagnosed subgroup: 87% overall treatment burden reduction (1.6 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)”
> “Dose response maintained throughout 2 years in favor of the Phase 3 dose”

Source: [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html)

<a id="topic-3.1.4.8.3-3"></a>

###### Injection-free proportions and lower-dose comparison at 2 years

| Outcome at 2 years | Quoted slide text |
| --- | --- |
| Phase 2b broad, 0 to 1 supplemental injection | “>50% of Participants Required 0-1 Supplemental Injection” |
| Phase 2b recently diagnosed, injection-free | “66% of Participants were Supplemental Injection-Free” |
| Phase 2b broad, 1E10 vg/eye, reduction and mean cumulative injections | “69%” and “3.7” |
| Phase 2b recently diagnosed, 1E10 vg/eye, reduction and mean cumulative injections | “73%” and “3.3” |
| Phase 2b broad, 3E10 vg/eye, injection-free | “46%” |

Source: [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="topic-3.1.4.8.3-4"></a>

###### Visual acuity and anatomy through 2 years

> “Consistent maintenance of best corrected visual acuity (BCVA) Consistent control of central subfield thickness (CST) as measured by optical coherence tomography”

Source: [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html)

<a id="topic-3.1.4.8.3-5"></a>

###### Mean cumulative supplemental injections through 1.5 years

| Population and dose | Through year 1 | Through year 1.5 |
| --- | --- | --- |
| Phase 2b broad, 3E10 vg/eye (n=30) | “1.0 (83% reduction)” | “1.6 (82% reduction)” |
| Phase 2b broad, 1E10 vg/eye (n=15) | “1.4 (77% reduction)” | “2.4 (73% reduction)” |
| Recently diagnosed, 3E10 vg/eye (n=15) | “0.3 (94% reduction)” | “0.7 (92% reduction)” |
| Recently diagnosed, 1E10 vg/eye (n=11) | “1.4 (77% reduction)” | “2.1 (77% reduction)” |

Source: [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)

> “76% received 2 or fewer injections over 1.5 years”
> “87% received 2 or fewer injections over 1.5 years”

Source: [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)

<a id="topic-3.1.4.8.3-6"></a>

###### Supplemental injections by 6-month interval

> “Phase 2b Subgroup: Recently Diagnosed (Phase 3 comparable) 0.1 0.2 0.4 pending Phase 2b: Broad 0.4 0.6 0.6 pending”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="topic-3.1.4.8.3-7"></a>

###### 52-week results at the planned Phase 3 dose

| Outcome at week 52 | Phase 2b broad (n=30) and recently diagnosed subgroup (n=15) |
| --- | --- |
| Treatment burden, broad | “83% reduction, representing 0.97 mean supplemental injections per patient over 52-weeks vs. 6.0 injections projected with on-label aflibercept 2 mg Q8W 70% 0-1 injection 57% injection-free” |
| BCVA, broad | “Improved and maintained best corrected visual acuity (BCVA) of +2.2 letters” |
| CST, broad | “Durable central subfield thickness (CST) improvement with fewer fluctuations, as measured by optical coherence tomography (OCT), of -11 µm; -13 µm in supplemental injection-free patients” |
| Treatment burden, recently diagnosed | “94% reduction, representing 0.33 mean supplemental injections per patient over 52-weeks vs. 6.0 injections projected with on-label aflibercept 2 mg Q8W 87% 0-1 injection 80% injection-free” |
| BCVA, recently diagnosed | “Improved and maintained BCVA of +3.1 letters” |
| CST, recently diagnosed | “Durable CST improvement with fewer fluctuations, as measured by OCT, of -10 µm; -20 µm in supplemental injection-free patients” |

Source: [4D Molecular Therapeutics PRISM Phase 2b 52-week results announcement (2025)](https://www.globenewswire.com/news-release/2025/02/08/3023106/0/en/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-durability-data-supporting-4d-150-4front-global-registration-program.html)

<a id="topic-3.1.4.8.3-8"></a>

###### BCVA at week 52 without censoring

> “Week 52 mean change in BCVA without censoring, +1.0 letters.”
> “Week 52 mean change in BCVA without censoring, +2.4 letters.”

Source: [Pieramici (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis-2025-PRISM-Ph2b-Dante_08-Feb-2025_vFF-1.pdf)

<a id="topic-3.1.4.8.3-9"></a>

###### Earlier Kaplan-Meier estimates at week 52 in the broad cohort (September 2024 data cutoff)

> “Phase 2b Broad (n=30, through 52 weeks): 89% overall reduction in annualized injections 80% received 0 or 1 injection* 70% injection-free*”

Source: [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and)

<a id="topic-3.1.4.8.3-10"></a>

###### Earlier Kaplan-Meier estimates at week 52 in the recently diagnosed cohort (September 2024 data cutoff)

> “(n=15, through 52 weeks): 98% overall reduction in annualized injections 100% received 0 or 1 injection* 87% injection-free*”

Source: [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and)

<a id="topic-3.1.4.8.3-11"></a>

###### 24-week landmark results

> “89% reduction in mean annualized injection rate 93% received 0 or 1 injection 77% injection-free; dose response evident (60% on low dose arm)”
> “BCVA dose response demonstrated in favor of 3E10 vg/eye dose: +5.7 letter improvement in BCVA for patients in planned Phase 3 dose arm vs low dose arm”

Source: [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)

| Outcome, average of weeks 20 and 24 | 4D-150 3E10 vg/eye | 4D-150 1E10 vg/eye |
| --- | --- | --- |
| Adjusted mean (95% CI) change in BCVA, ETDRS letters | “+3.5 (1.1, 5.8)” | “–2.2 (–5.9, 1.4)” |
| Adjusted mean (95% CI) change in CST, µm | “–9.2 (–30.8, 12.4)” | “+6.9 (–26.7, 40.6)” |

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="topic-3.1.4.8.3-12"></a>

###### Aqueous humor aflibercept concentrations across 3E10 vg/eye cohorts

> “Of 54 total subjects, 11 were non-evaluable at all visits due to supplemental injections. Of the 43 evaluable subjects, 29/43 (67%) had detectable AFLB levels at any visit; 14/43 (33%) were BLQ at any visit.”
> “Robust and durable expression during follow up ranging from 9 months (Phase 2b) to up to 2 years (Phase 1/2a);  Phase 2b levels consistent with the long-term trajectory in Phase 1/2a”

Source: [Pieramici (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis-2025-PRISM-Ph2b-Dante_08-Feb-2025_vFF-1.pdf)

> “Durable and stable aflibercept expression demonstrated, with up to two years of follow-up, with aqueous humor concentrations consistently within projected therapeutic range”

Source: [4D Molecular Therapeutics PRISM Phase 2b 52-week results announcement (2025)](https://www.globenewswire.com/news-release/2025/02/08/3023106/0/en/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-durability-data-supporting-4d-150-4front-global-registration-program.html)

<a id="topic-3.1.4.8.3-13"></a>

###### Supplemental injections through 32 weeks at the September 2024 data cutoff

> “As of September 3, 2024, the duration of follow up ranged from 32 to 52 weeks.”
> “Through 32 weeks of follow-up (data available for all participants), 73% remained injection free and 93% received ≤1 injection.”

Source: [ARVO Annual Meeting (2025)](https://iovs.arvojournals.org/article.aspx?articleid=2804417)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Safety at the planned Phase 3 dose across PRISM through 2 to more than 4 years

> “Safety Data for Phase 3 Dose in Overall PRISM Phase 1/2a & 2b Clinical Trial (n=71) 4D-150 continues to be well tolerated: Intraocular inflammation: As previously reported, within approximately the first 6 months (28 weeks) post-4D-150 dosing, 2.8% (2 of 71) of patients had 4D-150-related 1+ (mild) intraocular inflammation (IOI) (SUN/NEI scales), which were transient 1+ vitreous cells noted at a single timepoint Following the first 28 weeks post-4D-150 dosing, no new cases of inflammation with 2 to more than 4 years of follow-up on all patients as of the data cutoff No 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis or choroidal effusions observed to date”

Source: [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html)

> “No 4D-150–related serious adverse events”
> “1+ VC cell in 1 patient at Week 4 & 1 patient Week 28.”

Source: [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="topic-3.1.4.8.5-2"></a>

###### Steroid prophylaxis completion across Phase 3-dose participants

> “99% (70 of 71) completed prophylactic topical steroid taper on schedule”
> “99% (70 of 71) remain completely off steroids”
> “Intraocular inflammation defined as presence of ≥1 anterior chamber or vitreous white blood cells on SUN/NEI scale.”

Source: [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)

<a id="topic-3.1.4.8.5-3"></a>

###### Endophthalmitis attributed to a supplemental aflibercept injection

> “Supplemental aflibercept injection-related case of endophthalmitis (presumed bacterial infection), resolved over following 2 visits”

Source: [Khanani (2024d)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_EURETINA-2024_PRISM_Presentation_9_17_2459.pdf)

<a id="topic-3.1.4.8.5-4"></a>

###### Inflammation at the 24-week analysis, including the lower dose

> “No vitreous inflammation in 14 of 15 patients, one patient with mild to moderate inflammation (1 of 45 total, ~2% overall); vitreous cells also observed in untreated fellow eye No 4D-150–related serious adverse events (SAEs) or study eye SAEs No hypotony, retinal vasculitis, choroidal effusions, retinal artery occlusions”

Source: [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)

> “Assessed as 2+ by primary investigator one day after initial assessment as 3+ by sub-investigator; 1+ vitreous cells observed in the contralateral eye; participant had a history of syphilis (reportedly treated).”

Source: [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf)

<a id="topic-3.1.4.8.5-5"></a>

###### Treatment-emergent adverse event frequencies

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The Population Extension is an open-label, non-randomized cohort of 45 participants (30 at 3E10 vg/eye and 15 at 1E10 vg/eye) with sequential dose assignment and no concurrent aflibercept control; 13 of the 30 participants at 3E10 vg/eye came from an alternative steroid cohort, and three different prophylactic corticosteroid regimens were used. Treatment burden reduction is calculated against a projected on-label aflibercept every-8-weeks schedule (6.0 injections at 52 weeks and 12.0 at 2 years) derived from a single-arm model, not against observed injections in a comparator arm, and the 4D-150 arms received scheduled aflibercept at Day -7 and Day 28. Reported values changed across data cutoffs for the same timepoint (for example, 70% injection-free through 52 weeks by Kaplan-Meier estimate in September 2024 versus 57% at the January 2025 cutoff), and the 3E10 vg/eye reduction declined from 83% at 1 year to 78% at 2 years, with 46% injection-free at 2 years. The week 52 BCVA gain was +2.2 letters with censoring of cataract or surgery-confounded assessments and +1.0 letter without censoring; 2-year BCVA and CST results were presented only as figures. The recently diagnosed subgroup most comparable to the Phase 3 population includes only 15 participants. Aqueous humor aflibercept was below the limit of quantitation at any visit in 14 of 43 evaluable participants (33%). Pooled safety across 71 participants at 3E10 vg/eye is too small to detect uncommon events, adverse event frequency tables have not been released, and no peer-reviewed full publication or patient-reported outcome data were identified.

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270); [Maturi (2024)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf); [4D Molecular Therapeutics wet AMD development day announcement (2024)](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and); [4D Molecular Therapeutics PRISM Phase 2b 52-week results announcement (2025)](https://www.globenewswire.com/news-release/2025/02/08/3023106/0/en/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study-and-long-term-durability-data-supporting-4d-150-4front-global-registration-program.html); [Pieramici (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/Angiogenesis-2025-PRISM-Ph2b-Dante_08-Feb-2025_vFF-1.pdf); [4D Molecular Therapeutics PRISM Phase 2b 2-year data announcement (2026)](https://www.globenewswire.com/news-release/2026/07/18/3329368/0/en/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broad-wet-amd-population.html); [Awh (2026)](https://4dmoleculartherapeutics.com/wp-content/uploads/Pres_ASRS_PRISM2b24M_Awh_VF.pdf)

<a id="heading-3.1.5"></a>

#### 3.1.5 PRISM Phase 1 Dose Exploration

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Objective of the dose exploration stage

> “OBJECTIVE:  EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY”

Source: [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)

<a id="topic-3.1.5.1-2"></a>

###### Registered dose escalation objective

> “In Dose Escalation, the safety and tolerability of multiple dose levels of 4D-150 will be examined following an open-label, 3+3 dose escalation design (n=3-5 per dose level).”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registry dates for the overall PRISM trial

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2021-12-09” |
| Primary completion (estimated) | “2027-03” |
| Study completion (estimated) | “2031-01” |

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.5.2-2"></a>

###### Data cutoffs of the dose exploration analyses

> “All data below are as of the data cutoff date of April 3, 2023”

Source: [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html)

> “As of the data cutoff date of July 3, 2023, all patients had completed follow-up through at least 36 weeks”

Source: [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Open-label, three-cohort dose exploration with DSMC review

> “Dose Escalation will be open-label.”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “Phase 1 Dose Exploration stage (n=15; three dose cohorts of 5 patients each at 3E10, 1E10 and 6E9 vg/eye) followed by a randomized Phase 2 Dose Expansion stage (n=50, randomized 2:2:1 to 3E10 vg/eye or 1E10 vg/eye of 4D-150 or aflibercept)”

Source: [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html)

<a id="topic-3.1.5.3-2"></a>

###### Long-term follow-up

> “Only subjects that received 4D-150 will then enter a long-term follow-up (LTFU) period to assess long-term safety of 4D-150 gene therapy and duration of clinical activity through year 5 (60 months).”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Key inclusion criteria for the dose exploration stage

| Criterion | Quoted slide text |
| --- | --- |
| Age | “Age ≥50 years” |
| Diagnosis | “CNV secondary to AMD” |
| Visual acuity | “≥25 (~20/320) and ≤78 (~20/32) ETDRS letters” |
| Anti-VEGF response | “Clinical response to anti-VEGF in prior 12 months” |
| Prior treatment | “≥6 anti-VEGF injections within the last 12 months” |

Source: [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)

<a id="topic-3.1.5.4-2"></a>

###### Retinal thickness criterion

> “≥300 µm or retinal fluid”

Source: [Awh (2025)](https://4dmoleculartherapeutics.com/wp-content/uploads/PRES_Awh_FloRetina_PRISM2418_VF.pdf)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Single intravitreal dose with topical corticosteroid taper

> “Patients received a single intravitreal dose of 4D-150. Topical corticosteroids were administered at tapering doses over 20 weeks”

Source: [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html)

<a id="topic-3.1.5.5-2"></a>

###### Registered dose escalation arm

> “4D-150 Dose Escalation up to 4 dose levels”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

<a id="topic-3.1.5.5-3"></a>

###### Supplemental anti-VEGF injection criteria

> “Anti-VEGF Injection Criteria: Loss of ≥10 letters from baseline in BCVA attributable to intraretinal or subretinal fluid; increase in CST >75 μm from baseline, confirmed by central reading center; presence of new vision-threatening hemorrhage due to wet AMD as determined by investigator.”

Source: [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary and key secondary endpoints of the dose exploration stage

> “Incidence and severity of TEAEs and SAEs”
> “% change, annualized anti-VEGF injection rate”
> “% of subjects requiring supplemental aflibercept”
> “Number of supplemental aflibercept injections”
> “BCVA change from baseline”
> “CST change from baseline”

Source: [Khanani et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/4D-150_ARVO-2023-Presentation_FINAL.pdf)

<a id="topic-3.1.5.6.1-2"></a>

###### Rationale for endpoint selection

No evidence found.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned and enrolled participants

> “In Dose Escalation, the safety and tolerability of multiple dose levels of 4D-150 will be examined following an open-label, 3+3 dose escalation design (n=3-5 per dose level).”

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270)

> “15 patients received a single intravitreal dose of 4D-150 across three dose cohorts (3E10, 1E10, and 6E9 vg/eye; n=5 each)”

Source: [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)

<a id="topic-3.1.5.7.1-2"></a>

###### Participants evaluable for supplemental injections at the highest dose

> “4 OF 4 (100%) EVALUABLE PARTICIPANTS INJECTION-FREE AT HIGHEST DOSE (3x1010 vg/EYE)”

Source: [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### All enrolled participants

> “ANALYSIS POPULATION: ALL ENROLLED PARTICIPANTS (N=15)”

Source: [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)

<a id="topic-3.1.5.7.2-2"></a>

###### Exclusions from BCVA analyses

> “Excludes patients with progressive cataract at time of BCVA measurement: aExcludes Patient 5 (not Phase 2 BCVA-eligible and not evaluable)”

Source: [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Follow-up completion and non-evaluable participants

> “As of 3 July 2023, all participants have completed ≥9 months of follow-up”
> “Progressive nuclear sclerotic cataract (Day -1), posterior subcapsular cataract (Week 16).”

Source: [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographics and baseline disease characteristics by dose cohort

| Characteristic | 3E10 vg/eye (N=5) | 1E10 vg/eye (N=5) | 6E9 vg/eye (N=5) | Total (N=15) |
| --- | --- | --- | --- | --- |
| Mean ±SE age, years | “79 ±3.9” | “79 ±4.1” | “76 ±4.9” | “78 ±4.0” |
| Female, n (%) | “5 (100)” | “3 (60)” | “3 (60)” | “11 (73)” |
| Mean ±SE BCVA, ETDRS letters | “55 ±7.4” | “65 ±3.4” | “75 ±4.0” | “65 ±3.6” |
| Mean ±SE central subfield thickness | “424 ±27.0” | “351 ±44.4” | “402 ±85.0” | “392 ±31.8” |
| Mean ±SE time since diagnosis, years | “3.5 ±0.8” | “2.6 ±0.5” | “4.7 ±1.4” | “3.6 ±1.0” |

Source: [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf)

<a id="topic-3.1.5.8.2-2"></a>

###### Prior anti-VEGF treatment burden

> “Enrolled participants had a high need for anti-VEGF therapy, with mean annualized injection rates ranging from 8 to 11 across cohorts prior to 4D-150 treatment”

Source: [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Summary: dose exploration results

At 24 weeks (data cutoff April 3, 2023), 4 of 5 participants (80%) at 3E10 vg/eye and 2 of 5 (40%) at each of 1E10 and 6E9 vg/eye were anti-VEGF injection-free, with changes in annualized injection rate of -84%, -68%, and -80%. At 36 weeks (data cutoff July 3, 2023), all 4 evaluable participants at 3E10 vg/eye were injection-free and the lower doses had a 71% reduction in mean annualized supplemental injection rate. The 3 participants at 3E10 vg/eye who were injection-free beyond 52 weeks remained injection-free through approximately 2 to 2.5 years (data cutoff June 24, 2024), with mean BCVA +1 letter and mean CST -110 µm from baseline in that dose cohort. Aflibercept was detected in the aqueous humor of 10 of 11 samples (91%) at week 12.

Source: [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html); [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html); [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)

<a id="topic-3.1.5.8.3-2"></a>

###### Clinical activity at 24 weeks by dose cohort

| Dose cohort | Anti-VEGF injection-free | Mean change in annualized anti-VEGF injection rate | Mean ±SE CST change (µm) | Mean ±SE BCVA change (letters) |
| --- | --- | --- | --- | --- |
| 3E10 vg/eye | “4 of 5 (80%)” | “(-)84%” | “-78 ±49” | “-4.0 ±4.5” |
| 1E10 vg/eye | “2 of 5 (40%)” | “(-)68%” | “+38 ±37” | “+1.4 ±3.5” |
| 6E9 vg/eye | “2 of 5 (40%)” | “(-)80%” | “+3 ±25” | “-1.2 ±4.2” |

Source: [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html)

<a id="topic-3.1.5.8.3-3"></a>

###### Clinical activity at 36 weeks

> “Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable patients injection-free) and a clinically meaningful reduction in mean central subfield thickness (CST) at 36 weeks in patient population with high anti-VEGF need”
> “Lower doses (1E10, 6E9 vg/eye) also highly active, with 5 of 10 patients requiring zero or one supplemental anti-VEGF injections and a 71% reduction in mean annualized supplemental anti-VEGF injection rate through 36 weeks”

Source: [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)

<a id="topic-3.1.5.8.3-4"></a>

###### Long-term follow-up of the 3E10 vg/eye cohort

> “All three Phase 1 patients treated with 3E10 vg/eye previously reported as injection-free beyond 52 weeks remain injection-free through ~2 to 2.5 years of follow-up Mean BCVA remains unchanged from baseline through ~2 years (+1 letter from baseline) Mean CST remains stable, without fluctuations, and decreased from baseline through ~2 years (-110 microns from baseline)”

Source: [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)

> “A single patient (1 of 4 evaluable patients in the 3E10 vg/eye cohort) met supplemental injection criterion beyond 36 weeks at a single timepoint.”

Source: [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)

<a id="topic-3.1.5.8.3-5"></a>

###### Aqueous humor aflibercept expression

> “4D-150-mediated expression of the aflibercept transgene protein was demonstrated in the aqueous humor (AH) of the eye at 12 weeks after 4D-150 injection in 91% (10 of 11) of patient samples evaluated to date1 Mean AH aflibercept concentrations dose-related, and predicted to be in therapeutic range for all cohorts”

Source: [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html)

<a id="topic-3.1.5.8.3-6"></a>

###### Pooled Phase 1/2a results

> “Phase 1/2a (at 2 years): 79% vs. 69%”

Source: [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

<a id="topic-3.1.5.8.3-7"></a>

###### Annualized injection rate before and after dosing in the 3E10 vg/eye cohort at the first interim cutoff

> “Follow-up was longest for the 3×1010 vg/eye cohort (12-40 weeks), which had a mean annualized anti-VEGF injection rate of 10.8 before 4D-150.”
> “Following 4D-150 injection, a 96.7% overall reduction in mean annualized anti-VEGF injection rate was observed, and 4 of 5 eyes were supplemental AFLB injection-free.”
> “Aqueous humor samples from the 3 eyes evaluated to date had detectable AFLB.”

Source: [ARVO Annual Meeting (2023)](https://iovs.arvojournals.org/article.aspx?articleid=2789669)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Safety through 24 weeks

> “No dose-limiting toxicities”
> “3x1010 vg/eye group: pigmented anterior chamber cells (mild, n=1), mixed vitreous cells (mild, n=1)”
> “No hypotony, no intraocular inflammation requiring intervention, no endophthalmitis, no retinal vasculitis, no choroidal effusions, no retinal artery occlusion”

Source: [Khanani et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/4D-150_ARVO-2023-Presentation_FINAL.pdf)

> “14 of 15 patient had no inflammation reported; one patient had a single episode of asymptomatic trace mixed vitreous cells that resolved without intervention 14 of 15 patients completed the protocol-mandated 20-week topical corticosteroid taper and did not receive further steroids; a single patient continued beyond 20 weeks by the treating physician for asymptomatic non-inflammatory trace pigmented cells”

Source: [4D Molecular Therapeutics PRISM ARVO 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/04/27/2656152/0/en/4DMT-Presents-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ARVO-2023.html)

<a id="topic-3.1.5.8.5-2"></a>

###### Safety through 36 weeks

> “4D-150 was well tolerated, with no reported Grade ≥1 inflammatory cells and no hypotony, dose-limiting toxicities, or treatment-related serious adverse events”
> “Patient was well controlled on the basis of both BCVA and CST prior to developing a retinal hemorrhage, which has resolved with no significant change from baseline in BCVA (reported as “not related” to the test article)”

Source: [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html)

<a id="topic-3.1.5.8.5-3"></a>

###### Long-term safety through up to 2.5 years

> “Safety results maintained in all 15 patients treated to the cutoff date (up to 2.5 years of follow-up) with no new inflammation and no change in steroid status”

Source: [4D Molecular Therapeutics PRISM Population Extension 24-week results announcement (2024)](https://www.globenewswire.com/news-release/2024/07/17/2914359/0/en/4DMT-Announces-Positive-Phase-2-PRISM-Interim-Results-for-Intravitreal-4D-150-in-a-Broad-Wet-AMD-Population-Affirming-Favorable-Safety-Profile-and-Robust-Clinical-Activity.html)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The dose exploration stage is an open-label, uncontrolled study of 15 participants (5 per dose cohort), so dose-response and efficacy estimates rest on very small numbers; at the 36-week analysis, only 4 participants at 3E10 vg/eye were evaluable for supplemental injections, and BCVA analyses excluded participants with progressive cataract. Treatment burden reduction was measured against each participant's injection history in the prior 12 months, which is subject to regression to the mean in a population selected for 6 or more injections, rather than against a concurrent comparator. Baseline characteristics differed across cohorts (for example, mean BCVA 55, 65, and 75 letters and mean time since diagnosis 3.5, 2.6, and 4.7 years), and the population had severe, recalcitrant disease unlike the recently diagnosed or treatment-naive population of the Phase 3 trials. Long-term results after mid-2024 are reported only pooled with the Phase 2a dose expansion. Results are available only from company announcements and congress presentations, with no peer-reviewed full publication and no patient-reported outcomes identified.

Source: [ClinicalTrials.gov NCT05197270](https://clinicaltrials.gov/study/NCT05197270); [Kay et al. (2023)](https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_ASRS-2023_Kay_4D-150-PRISM-Trial.pdf); [4D Molecular Therapeutics PRISM ASRS 2023 interim data announcement (2023)](https://www.globenewswire.com/news-release/2023/07/29/2714505/0/en/4DMT-Presents-Additional-Positive-Interim-Data-from-Intravitreal-4D-150-Phase-1-2-PRISM-Clinical-Trial-in-Patients-with-Wet-AMD-at-ASRS-2023.html); [4D Molecular Therapeutics PRISM long-term data announcement (2025)](https://www.globenewswire.com/news-release/2025/11/06/3182290/0/en/4DMT-Announces-Positive-Long-Term-Data-from-Phase-1-2-PRISM-Clinical-Trial-in-Wet-AMD-Supporting-4D-150-s-Potential-as-a-Backbone-Therapy-with-Consistent-and-Durable-Benefit-over-M.html)

## Related pages
- [4D-150: Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration.md)
- [4D-150 in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [4D-150: Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/executive-summary.md)
- [4D-150 in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [4D-150 in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/economics.md)
- [4D-150 in Neovascular age-related macular degeneration: References](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/references.md)
- [4D-150 in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/prevalence.md)
- [4D-150 in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
